Up to Date Stocks in Focus: United States Steel Corporation (NYSE:X), FibroGen, Inc. (NASDAQ:FGEN), Pebblebrook â€¦ (journalfinance.net)
A number of research analysts recently commented on FGEN shares. Zacks Investment Research downgraded FibroGen from a "hold" rating to a "sell" rating in a report on Monday, May 14th. Mizuho reissued a "buy" rating and issued a $74.00 price target on shares of FibroGen in a report on Tuesday, June 19th. ValuEngine downgraded FibroGen from a "strong-buy" rating to a "buy" rating in a report on Thursday, August 2nd. Finally, BidaskClub raised FibroGen from a "hold" rating to a "buy" rating in a report on Thursday, May 24th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company's stock. The stock presently has an average rating of "Buy" and an average target price of $77.60.
Shares of FGEN opened at $60.55 on Friday. FibroGen has a one year low of $40.26 and a one year high of $68.55. The stock has a market capitalization of $5.06 billion, a P/E ratio of -35.00 and a beta of 1.88. The company has a quick ratio of 7.95, a current ratio of 7.95 and a debt-to-equity ratio of 0.19.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $0.31. FibroGen had a negative return on equity of 22.60% and a negative net margin of 85.59%. The firm had revenue of $43.95 million for the quarter, compared to analysts' expectations of $28.70 million. research analysts anticipate that FibroGen will post -1.32 EPS for the current year.
In other FibroGen news, SVP Pat Cotroneo sold 14,987 shares of the company's stock in a transaction that occurred on Monday, May 21st. The stock was sold at an average price of $55.04, for a total transaction of $824,884.48. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink . Also, Director Roberto Pedro Rosenkranz sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, June 21st. The shares were sold at an average price of $63.65, for a total value of $63,650.00. Following the sale, the director now owns 33,700 shares in the company, valued at approximately $2,145,005. The disclosure for this sale can be found here . Insiders have sold 263,230 shares of company stock worth $16,170,636 in the last 90 days. 8.96% of the stock is currently owned by insiders.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. FibroGen FibroGe